JP2015514739A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514739A5
JP2015514739A5 JP2015506258A JP2015506258A JP2015514739A5 JP 2015514739 A5 JP2015514739 A5 JP 2015514739A5 JP 2015506258 A JP2015506258 A JP 2015506258A JP 2015506258 A JP2015506258 A JP 2015506258A JP 2015514739 A5 JP2015514739 A5 JP 2015514739A5
Authority
JP
Japan
Prior art keywords
agent
composition
radiprodil
antagonist
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015506258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514739A (ja
JP6042968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/058212 external-priority patent/WO2013156614A1/en
Publication of JP2015514739A publication Critical patent/JP2015514739A/ja
Publication of JP2015514739A5 publication Critical patent/JP2015514739A5/ja
Application granted granted Critical
Publication of JP6042968B2 publication Critical patent/JP6042968B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015506258A 2012-04-20 2013-04-19 パーキンソン病の処置方法 Expired - Fee Related JP6042968B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636054P 2012-04-20 2012-04-20
US61/636,054 2012-04-20
PCT/EP2013/058212 WO2013156614A1 (en) 2012-04-20 2013-04-19 Methods for treating parkinson's disease

Publications (3)

Publication Number Publication Date
JP2015514739A JP2015514739A (ja) 2015-05-21
JP2015514739A5 true JP2015514739A5 (enExample) 2016-03-24
JP6042968B2 JP6042968B2 (ja) 2016-12-14

Family

ID=48182898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015506258A Expired - Fee Related JP6042968B2 (ja) 2012-04-20 2013-04-19 パーキンソン病の処置方法

Country Status (9)

Country Link
US (2) US9387212B2 (enExample)
EP (1) EP2838530B1 (enExample)
JP (1) JP6042968B2 (enExample)
KR (1) KR20140146217A (enExample)
CN (1) CN104321057B (enExample)
AU (1) AU2013251079B2 (enExample)
CA (1) CA2869216A1 (enExample)
ES (1) ES2627541T3 (enExample)
WO (1) WO2013156614A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044323A1 (en) 2014-09-15 2016-03-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016106135A1 (en) 2014-12-23 2016-06-30 Cerecor, Inc. Compounds, compositions and methods
MX380424B (es) 2015-06-01 2025-03-12 Rugen Holdings Cayman Ltd Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
WO2017136375A1 (en) * 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
CN106214652A (zh) * 2016-08-31 2016-12-14 安徽省润生医药股份有限公司 一种含有伊曲茶碱的药物组合物
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
CN108864114B (zh) 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
WO2025137652A2 (en) 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69532482T2 (de) * 1995-05-26 2004-11-25 Pfizer Inc. Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
AU781591B2 (en) 1999-05-10 2005-06-02 Princeton University Compositions and methods for improving learning and memory
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールnmda/nr2bアンタゴニストを使用する疼痛の治療方法
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
GB0015488D0 (en) 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
WO2002009736A1 (en) 2000-07-27 2002-02-07 Washington University Methods and agents for treating persistent pain
WO2002012892A2 (en) 2000-08-04 2002-02-14 Cis Biotech, Inc. Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療又は予防用nr2b受容体拮抗薬
DE60228969D1 (enExample) 2001-07-24 2008-10-30 Richter Gedeon Nyrt
WO2003084931A1 (en) 2002-04-02 2003-10-16 Merck & Co., Inc. 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2506568A1 (en) 2002-11-22 2004-06-10 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003303042A1 (en) 2002-12-17 2004-07-09 Pfizer Inc. 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA05010824A (es) 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
CA2527093C (en) 2003-06-04 2009-10-20 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
US7452893B2 (en) 2003-08-15 2008-11-18 Merck & Co., Inc. 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists
WO2005019222A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
JP4737418B2 (ja) 2003-09-25 2011-08-03 塩野義製薬株式会社 Nmda受容体拮抗作用を有するピペリジン誘導体
WO2005035522A1 (en) 2003-10-08 2005-04-21 Pfizer Japan, Inc. 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
US20070167452A1 (en) 2004-02-11 2007-07-19 Pfizer, Inc. Therapeutic amide derivatives
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
DE602005004142T2 (de) * 2004-05-24 2009-01-02 F. Hoffmann-La Roche Ag 4-hydroxy-4-methylpiperidin-1-carbonsäure-(4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)-amid
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
CN1993363A (zh) 2004-08-03 2007-07-04 默克公司 1,3-二取代的杂芳基nmda/nr2b拮抗剂
WO2006083949A2 (en) 2005-02-01 2006-08-10 University Of Medicine And Dentistry Of New Jersey Sepsis prevention through adenosine receptor modulation
WO2006113471A2 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
WO2006124770A2 (en) 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
JPWO2006129626A1 (ja) 2005-05-30 2009-01-08 協和醗酵工業株式会社 [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
WO2007006157A1 (en) 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
EP1954259A2 (en) 2005-11-29 2008-08-13 Hammersmith Imanet, Ltd Amidine derivatives for in vivo imaging
WO2007063839A1 (ja) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP2038285B1 (en) * 2006-06-26 2010-02-17 Schering Corporation Adenosine a2a receptor antagonists
JP2010509258A (ja) 2006-11-09 2010-03-25 セントレ・ドゥ・レシェルシェ・パブリック・ドゥ・ラ・サン アデノシンアンタゴニストの使用
EP2162742B1 (en) 2007-06-19 2015-09-30 Rajiv Gandhi Centre For Biotechnology Assay for detection of transient intracellular ca2+
WO2009025265A1 (ja) 2007-08-21 2009-02-26 Shionogi & Co., Ltd. ピペラジン誘導体
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US8017614B2 (en) 2007-10-24 2011-09-13 Janssen Pharmaceutica N.V. Arylindenopyrimidines compound and use as an adenosine A2a receptor antagonists
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
NZ588698A (en) 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US8684624B2 (en) 2008-07-01 2014-04-01 Saint-Gobain Performance Plastics Rencol Limited Tolerance ring
EP2144462A1 (en) 2008-07-09 2010-01-13 Nokia Siemens Networks OY Reduced resource allocation parameter signalling
EP2297715A1 (de) 2008-07-09 2011-03-23 Siemens Aktiengesellschaft Verfahren, kommunikationsverbund und software zum auffinden von gesuchten objekten
CA2734859A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating cns disorders
RU2011115815A (ru) 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
US8536306B2 (en) 2008-10-01 2013-09-17 The Scripps Research Institute Human A2A adenosine receptor crystals and uses thereof
US8282042B2 (en) 2009-06-22 2012-10-09 The Boeing Company Skin panel joint for improved airflow
US8301311B2 (en) 2009-07-06 2012-10-30 Siemens Aktiengesellschaft Frequency-responsive wind turbine output control
US20110007639A1 (en) 2009-07-10 2011-01-13 Qualcomm Incorporated Methods and apparatus for detecting identifiers
US20110105540A1 (en) 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
DE102010026274A1 (de) 2010-07-06 2012-01-12 Voith Patent Gmbh Bremsanlage und Verfahren zum Einstellen eines Bremsmomentes einer solchen
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物

Similar Documents

Publication Publication Date Title
JP2015514739A5 (enExample)
JP2012255026A5 (enExample)
JP2013542247A5 (enExample)
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
JP2013014622A5 (enExample)
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
JP2013509429A5 (enExample)
JP2017504611A5 (enExample)
JP2007145875A5 (enExample)
JP2012502037A5 (enExample)
JP2009525343A5 (enExample)
HRP20160135T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka
JP2014521735A5 (enExample)
JP2013518107A5 (enExample)
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
JP2017519019A5 (enExample)
JP2012193216A5 (enExample)
JP2014507446A5 (enExample)
JP2013542246A5 (enExample)
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2016539156A5 (enExample)
JP2014218522A5 (enExample)
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент